DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Kim SB, Dent R, Im SA. et al.
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Oncol 2017;
18: 1360-1372
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.